Chia‐Yen Lin
Papers
6
Total Citations
98
H-Index
6
About
Chia-Yen Lin is a leading urologic oncology researcher whose work bridges genetic susceptibility and surgical innovation in prostate and renal cancers. His research primarily focuses on the role of long non-coding RNA (lncRNA) polymorphisms—particularly GAS5, MALAT1, and H19—in prostate cancer progression and prognosis. In a landmark 2019 study (27 citations), Lin demonstrated that the GAS5 rs145204276 variant significantly influences prostate cancer susceptibility and clinicopathologic features, offering a potential biomarker for risk stratification. His 2021 work on MALAT1 polymorphisms (15 citations) further revealed associations with lymph node metastasis, advancing personalized prognosis. Beyond genetics, Lin has pioneered robotic surgical techniques, notably reporting the first long-term outcomes of robotic partial nephrectomy for renal angiomyolipoma (17 citations), showing excellent renal function preservation. His 2014 review on robotic urologic surgery (14 citations) helped establish best practices for da Vinci system applications. Lin’s integrated approach—combining molecular epidemiology with minimally invasive surgery—has produced over 100 citations across his most influential papers, positioning him as a key figure in translating genomic discoveries into improved urologic cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2Long-term outcome of robotic partial nephrectomy for renal angiomyolipoma17 citations · 2016
- 3
- 4
- 5Application in robotic urologic surgery14 citations · 2014
- 6